HB0457enr 95TH GENERAL ASSEMBLY



 


 
HB0457 Enrolled LRB095 04451 RLC 26428 b

1     AN ACT concerning criminal law.
 
2     Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
 
4     Section 5. The Illinois Controlled Substances Act is
5 amended by changing Section 204 as follows:
 
6     (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
7     Sec. 204. (a) The controlled substances listed in this
8 Section are included in Schedule I.
9     (b) Unless specifically excepted or unless listed in
10 another schedule, any of the following opiates, including their
11 isomers, esters, ethers, salts, and salts of isomers, esters,
12 and ethers, whenever the existence of such isomers, esters,
13 ethers and salts is possible within the specific chemical
14 designation:
15         (1) Acetylmethadol;
16         (1.1) Acetyl-alpha-methylfentanyl
17     (N-[1-(1-methyl-2-phenethyl)-
18     4-piperidinyl]-N-phenylacetamide);
19         (2) Allylprodine;
20         (3) Alphacetylmethadol, except
21     levo-alphacetylmethadol (also known as levo-alpha-
22     acetylmethadol, levomethadyl acetate, or LAAM);
23         (4) Alphameprodine;

 

 

HB0457 Enrolled - 2 - LRB095 04451 RLC 26428 b

1         (5) Alphamethadol;
2         (6) Alpha-methylfentanyl
3     (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
4     propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
5     propanilido) piperidine;
6         (6.1) Alpha-methylthiofentanyl
7     (N-[1-methyl-2-(2-thienyl)ethyl-
8     4-piperidinyl]-N-phenylpropanamide);
9         (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
10         (7) 1-methyl-4-phenyl-4-proprionoxypiperidine (MPPP);
11         (7.1) PEPAP
12     (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
13         (8) Benzethidine;
14         (9) Betacetylmethadol;
15         (9.1) Beta-hydroxyfentanyl
16     (N-[1-(2-hydroxy-2-phenethyl)-
17     4-piperidinyl]-N-phenylpropanamide);
18         (10) Betameprodine;
19         (11) Betamethadol;
20         (12) Betaprodine;
21         (13) Clonitazene;
22         (14) Dextromoramide;
23         (15) Diampromide;
24         (16) Diethylthiambutene;
25         (17) Difenoxin;
26         (18) Dimenoxadol;

 

 

HB0457 Enrolled - 3 - LRB095 04451 RLC 26428 b

1         (19) Dimepheptanol;
2         (20) Dimethylthiambutene;
3         (21) Dioxaphetylbutyrate;
4         (22) Dipipanone;
5         (23) Ethylmethylthiambutene;
6         (24) Etonitazene;
7         (25) Etoxeridine;
8         (26) Furethidine;
9         (27) Hydroxpethidine;
10         (28) Ketobemidone;
11         (29) Levomoramide;
12         (30) Levophenacylmorphan;
13         (31) 3-Methylfentanyl
14     (N-[3-methyl-1-(2-phenylethyl)-
15     4-piperidyl]-N-phenylpropanamide);
16         (31.1) 3-Methylthiofentanyl
17     (N-[(3-methyl-1-(2-thienyl)ethyl-
18     4-piperidinyl]-N-phenylpropanamide);
19         (32) Morpheridine;
20         (33) Noracymethadol;
21         (34) Norlevorphanol;
22         (35) Normethadone;
23         (36) Norpipanone;
24         (36.1) Para-fluorofentanyl
25     (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
26     4-piperidinyl]propanamide);

 

 

HB0457 Enrolled - 4 - LRB095 04451 RLC 26428 b

1         (37) Phenadoxone;
2         (38) Phenampromide;
3         (39) Phenomorphan;
4         (40) Phenoperidine;
5         (41) Piritramide;
6         (42) Proheptazine;
7         (43) Properidine;
8         (44) Propiram;
9         (45) Racemoramide;
10         (45.1) Thiofentanyl
11     (N-phenyl-N-[1-(2-thienyl)ethyl-
12     4-piperidinyl]-propanamide);
13         (46) Tilidine;
14         (47) Trimeperidine;
15         (48) Beta-hydroxy-3-methylfentanyl (other name:
16     N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
17     N-phenylpropanamide).
18     (c) Unless specifically excepted or unless listed in
19 another schedule, any of the following opium derivatives, its
20 salts, isomers and salts of isomers, whenever the existence of
21 such salts, isomers and salts of isomers is possible within the
22 specific chemical designation:
23         (1) Acetorphine;
24         (2) Acetyldihydrocodeine;
25         (3) Benzylmorphine;
26         (4) Codeine methylbromide;

 

 

HB0457 Enrolled - 5 - LRB095 04451 RLC 26428 b

1         (5) Codeine-N-Oxide;
2         (6) Cyprenorphine;
3         (7) Desomorphine;
4         (8) Diacetyldihydromorphine (Dihydroheroin);
5         (9) Dihydromorphine;
6         (10) Drotebanol;
7         (11) Etorphine (except hydrochloride salt);
8         (12) Heroin;
9         (13) Hydromorphinol;
10         (14) Methyldesorphine;
11         (15) Methyldihydromorphine;
12         (16) Morphine methylbromide;
13         (17) Morphine methylsulfonate;
14         (18) Morphine-N-Oxide;
15         (19) Myrophine;
16         (20) Nicocodeine;
17         (21) Nicomorphine;
18         (22) Normorphine;
19         (23) Pholcodine;
20         (24) Thebacon.
21     (d) Unless specifically excepted or unless listed in
22 another schedule, any material, compound, mixture, or
23 preparation which contains any quantity of the following
24 hallucinogenic substances, or which contains any of its salts,
25 isomers and salts of isomers, whenever the existence of such
26 salts, isomers, and salts of isomers is possible within the

 

 

HB0457 Enrolled - 6 - LRB095 04451 RLC 26428 b

1 specific chemical designation (for the purposes of this
2 paragraph only, the term "isomer" includes the optical,
3 position and geometric isomers):
4         (1) 3,4-methylenedioxyamphetamine
5     (alpha-methyl,3,4-methylenedioxyphenethylamine,
6     methylenedioxyamphetamine, MDA);
7         (1.1) Alpha-ethyltryptamine
8     (some trade or other names: etryptamine;
9     MONASE; alpha-ethyl-1H-indole-3-ethanamine;
10     3-(2-aminobutyl)indole; a-ET; and AET);
11         (2) 3,4-methylenedioxymethamphetamine (MDMA);
12         (2.1) 3,4-methylenedioxy-N-ethylamphetamine
13     (also known as: N-ethyl-alpha-methyl-
14     3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
15     and MDEA);
16         (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
17         (4) 3,4,5-trimethoxyamphetamine (TMA);
18         (5) (Blank);
19         (6) Diethyltryptamine (DET);
20         (7) Dimethyltryptamine (DMT);
21         (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
22         (9) Ibogaine  (some trade and other names:
23     7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
24     6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
25     indole; Tabernanthe iboga);
26         (10) Lysergic acid diethylamide;

 

 

HB0457 Enrolled - 7 - LRB095 04451 RLC 26428 b

1         (10.5) Salvia divinorum (meaning all parts of the plant
2     presently classified botanically as Salvia divinorum,
3     whether growing or not, the seeds thereof, any extract from
4     any part of that plant, and every compound, manufacture,
5     salts, isomers, and salts of isomers whenever the existence
6     of such salts, isomers, and salts of isomers is possible
7     within the specific chemical designation, derivative,
8     mixture, or preparation of that plant, its seeds or
9     extracts);
10         (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
11         (12) Peyote (meaning all parts of the plant presently
12     classified botanically as Lophophora williamsii williemaii
13     Lemaire, whether growing or not, the seeds thereof, any
14     extract from any part of that plant, and every compound,
15     manufacture, salts, derivative, mixture, or preparation of
16     that plant, its seeds or extracts);
17         (13) N-ethyl-3-piperidyl benzilate (JB 318);
18         (14) N-methyl-3-piperidyl benzilate;
19         (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
20     (also known as N-hydroxy-alpha-methyl-
21     3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
22         (15) Parahexyl; some trade or other names:
23     3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
24     dibenzo (b,d) pyran; Synhexyl;
25         (16) Psilocybin;
26         (17) Psilocyn;

 

 

HB0457 Enrolled - 8 - LRB095 04451 RLC 26428 b

1         (18) Alpha-methyltryptamine (AMT);
2         (19) 2,5-dimethoxyamphetamine
3     (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
4         (20) 4-bromo-2,5-dimethoxyamphetamine
5     (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
6     4-bromo-2,5-DMA);
7         (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
8     Some trade or other names: 2-(4-bromo-
9     2,5-dimethoxyphenyl)-1-aminoethane;
10     alpha-desmethyl DOB, 2CB, Nexus;
11         (21) 4-methoxyamphetamine
12     (4-methoxy-alpha-methylphenethylamine;
13     paramethoxyamphetamine; PMA);
14         (22) (Blank);
15         (23) Ethylamine analog of phencyclidine.
16     Some trade or other names:
17     N-ethyl-1-phenylcyclohexylamine,
18     (1-phenylcyclohexyl) ethylamine,
19     N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
20         (24) Pyrrolidine analog of phencyclidine. Some trade
21     or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
22     PHP;
23         (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
24         (26) 2,5-dimethoxy-4-ethylamphetamine
25     (another name: DOET);
26         (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

 

 

HB0457 Enrolled - 9 - LRB095 04451 RLC 26428 b

1     (another name: TCPy);
2         (28) (Blank);
3         (29) Thiophene analog of phencyclidine (some trade
4     or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
5     2-thienyl analog of phencyclidine; TPCP; TCP);
6         (30) Bufotenine (some trade or other names:
7     3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
8     3-(2-dimethylaminoethyl)-5-indolol;
9     5-hydroxy-N,N-dimethyltryptamine;
10     N,N-dimethylserotonin; mappine).
11     (e) Unless specifically excepted or unless listed in
12 another schedule, any material, compound, mixture, or
13 preparation which contains any quantity of the following
14 substances having a depressant effect on the central nervous
15 system, including its salts, isomers, and salts of isomers
16 whenever the existence of such salts, isomers, and salts of
17 isomers is possible within the specific chemical designation:
18         (1) mecloqualone;
19         (2) methaqualone; and
20         (3) gamma hydroxybutyric acid.
21     (f) Unless specifically excepted or unless listed in
22 another schedule, any material, compound, mixture, or
23 preparation which contains any quantity of the following
24 substances having a stimulant effect on the central nervous
25 system, including its salts, isomers, and salts of isomers:
26         (1) Fenethylline;

 

 

HB0457 Enrolled - 10 - LRB095 04451 RLC 26428 b

1         (2) N-ethylamphetamine;
2         (3) Aminorex (some other names:
3     2-amino-5-phenyl-2-oxazoline; aminoxaphen;
4     4-5-dihydro-5-phenyl-2-oxazolamine) and its
5     salts, optical isomers, and salts of optical isomers;
6         (4) Methcathinone (some other names:
7     2-methylamino-1-phenylpropan-1-one;
8     Ephedrone; 2-(methylamino)-propiophenone;
9     alpha-(methylamino)propiophenone; N-methylcathinone;
10     methycathinone; Monomethylpropion; UR 1431) and its
11     salts, optical isomers, and salts of optical isomers;
12         (5) Cathinone (some trade or other names:
13     2-aminopropiophenone; alpha-aminopropiophenone;
14     2-amino-1-phenyl-propanone; norephedrone);
15         (6) N,N-dimethylamphetamine (also known as:
16     N,N-alpha-trimethyl-benzeneethanamine;
17     N,N-alpha-trimethylphenethylamine);
18         (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
19     4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine).
20     (g) Temporary listing of substances subject to emergency
21 scheduling. Any material, compound, mixture, or preparation
22 that contains any quantity of the following substances:
23         (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
24     (benzylfentanyl), its optical isomers, isomers, salts,
25     and salts of isomers;
26         (2) N-[1(2-thienyl)

 

 

HB0457 Enrolled - 11 - LRB095 04451 RLC 26428 b

1    methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
2    its optical isomers, salts, and salts of isomers.
3 (Source: P.A. 90-382, eff. 8-15-97; 91-714, eff. 6-2-00;
4 revised 10-18-05.)